Is LL-37 safe during pregnancy or breastfeeding?

LL-37, like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

What should I look for in LL-37 sourcing and quality?

Acceptable LL-37 certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 4493 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

How long until I see results from LL-37?

Acute effects from LL-37 appear within the first week for downstream physiological adaptation. female hormonal and cyclical endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

What is the mechanism of action of LL-37?

Amphipathic α-helical peptide cleaved from hCAP-18 by proteinase 3. Disrupts microbial membranes electrostatically. Neutralises LPS. Modulates immune cell signalling via FPR2 and P2X7 receptors. Active against gram-positive, gram-negative, mycobacterial, and biofilm phenotypes. For female hormonal and cyclical applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Amphipathic α-helical peptide cleaved from hCAP-18 by proteinase 3. The female physiology interpretation focuses on the pathway-level detail rather than on any single high-level summary.

How should LL-37 be stored and reconstituted?

Lyophilised LL-37 stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

Home/ Compounds/ LL-37

LL-37

Women's Health

For women considering LL-37, the framework spans three life stages: reproductive, perimenopausal, and postmenopausal. Each carries distinct hormonal context and distinct monitoring requirements. The body's principal endogenous antimicrobial peptide — broad-spectrum activity against bacteria, fungi, viruses, and biofilms, plus immunomodulatory effects. The Variable; tissue-localised pharmacokinetic profile shapes how the compound is felt across follicular versus luteal phases in pre-menopausal users and how it integrates with HRT in older cohorts.

Female Physiology Applications

Mood (Cycle-Related)Body Composition (Female)Cardiovascular (Female)SleepFertility

Key Takeaways

Female-physiology lens: LL-37 response varies across follicular and luteal phases for premenopausal users; integrates with HRT in perimenopause and postmenopause.
Mechanism: Amphipathic α-helical peptide cleaved from hCAP-18 by proteinase 3.
Female monitoring: cycle-day-appropriate estradiol, progesterone, FSH, LH, prolactin, TSH, bone markers; pregnancy contraindication is default.
Female dose: 100-500 mcg daily subq for 4-8 weeks via subq/topical/nebulised; cycle-phase tracking for 1-2 cycles.
Female-physiology stack partners: Oxytocin, Kisspeptin, GHK-Cu.

Female Physiology Mechanism

Amphipathic α-helical peptide cleaved from hCAP-18 by proteinase 3. Disrupts microbial membranes electrostatically. Neutralises LPS. Modulates immune cell signalling via FPR2 and P2X7 receptors. Active against gram-positive, gram-negative, mycobacterial, and biofilm phenotypes. Female-physiology implications operate across three life-stage contexts: pre-menopausal cyclical users, the perimenopausal transition, and post-menopausal users on or off HRT. LL-37's response varies meaningfully across these contexts, as the subsections on cyclical context, perimenopause integration, fertility, and bone-and-cardiovascular signalling describe.

Cyclical and hormonal context

Female physiology is cyclical in a way that male physiology is not, and LL-37's effects often vary across follicular versus luteal phase. Even where the compound's pharmacology is not directly hormonal, the cyclical hormone background influences how it is metabolised, distributed, and felt. Pre-menopausal users should expect to track response by cycle phase for one or two cycles before settling on a fixed schedule.

Fertility and reproductive considerations

LL-37's effect on fertility-relevant endpoints — ovulation, ovarian reserve markers, uterine receptivity, lactation — deserves explicit consideration for women in the reproductive window. Most well-studied compounds have minimal direct effect on reproductive endpoints at therapeutic doses, but pregnancy and active conception remain explicit contraindications for most non-approved peptides.

Bone density and cardiovascular signalling

Two areas where female physiology diverges sharply post-menopause are bone remodelling and cardiovascular tone. LL-37's effect on these systems is one of the underweighted but practically important considerations for women using peptides through the menopausal transition. Bone-marker labs (CTX, P1NP) and cardiovascular indices (lipids, blood pressure, hsCRP) provide a tractable monitoring framework.

Female Physiology Applications

Mood (Cycle-Related)

Mood (Cycle-Related) is one of the dimensions on which women track LL-37 response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.

Libido (Female)

In the perimenopausal window, LL-37 for libido (female) produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.

Skin Health

For skin health in female users, LL-37 is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.

Hair Health

Hair Health is one of the dimensions on which women track LL-37 response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	100-500 mcg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	60-500 mcg	4–6 weeks initial cycle
Women's Health focus	SubQ	100-500 mcg	Daily SubQ for 4-8 weeks
Maintenance phase	SubQ	70-500 mcg	Ongoing with periodic pauses

Dose timing for LL-37 is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

LL-37 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from women's-health clinicians.

LL-37 + Oxytocin: Activates oxytocin receptors (OXTR) peripherally (uterine smooth muscle, mammary alveoli) and centrally (amygdala, hypothalamus, ventral tegmentum). Pairs naturally with LL-37's mechanism in female physiology protocols.
LL-37 + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with LL-37's mechanism in female physiology protocols.
LL-37 + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with LL-37's mechanism in female physiology protocols.
LL-37 + Epithalon: Identified by Khavinson in St. Pairs naturally with LL-37's mechanism in female physiology protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved Research: Preclinical + small human series

Site reactions common (peptide is cationic). Histamine-like flush possible. Caution in mast-cell-activation conditions.

Lens-specific safety considerations for female physiology use of LL-37: Site reactions common (peptide is cationic). Histamine-like flush possible. Caution in mast-cell-activation conditions. Additional female physiology monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

LL-37 — multifunctional antimicrobial peptide

PMID 16203862

Supporting

Cathelicidin LL-37 in immunity and inflammation

PMID 29503651

LL-37 vs Related Peptides

Compound	Profile	Onset	Best For
LL-37	Cathelicidin antimicrobial peptide	Variable; tissue-localised	Women's Health
Oxytocin	Posterior pituitary nonapeptide	~1-6 min plasma; CNS longer	The 'bonding hormone' — a posterior pituitary nonapeptide with effects on uterine contraction, lactation, and a wide range of social and sexual behaviour via central oxytocin receptors
Kisspeptin	Hypothalamic upstream regulator of GnRH	~28 min IV	The upstream master regulator of GnRH neurons — driving the entire HPG axis from above
PT-141	Melanocortin receptor agonist	~2-3 hr	An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women

Frequently Asked Questions

Can I use LL-37 alongside HRT?

Yes, in most cases. Integration with HRT — estrogen, progesterone, sometimes testosterone — is additive rather than competitive for most peptide compounds. Coordinating with a HRT-prescribing physician on dose timing and monitoring is the standard approach.

Will LL-37 affect contraceptive efficacy?

For most peptide compounds, contraceptive efficacy is not significantly affected. Compounds directly modulating the HPG axis (kisspeptin, gonadorelin) are exceptions and warrant alternative or additional contraceptive measures during use. LL-37's specific interaction follows its mechanism.

Does LL-37 affect bone density?

Several peptide compounds have measurable effects on bone-remodelling markers, particularly relevant for post-menopausal users. Where LL-37 specifically engages this pathway, paired pre-post DEXA or bone-marker tracking provides the cleanest evaluation. For most compounds the bone effect is secondary and develops over months.

Can I use LL-37 during pregnancy or while trying to conceive?

Most peptide therapeutics, including LL-37, do not have safety data supporting use during pregnancy or active conception. The default position is to discontinue at least 2–3 cycles before planned conception and to avoid throughout pregnancy and lactation unless specifically approved by a physician familiar with the indication.

What is the standard dosing protocol for LL-37?

Conventional LL-37 dosing is 100-500 mcg daily subq for 4-8 weeks via subq/topical/nebulised. For female hormonal and cyclical use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

How does LL-37 compare to Oxytocin and Kisspeptin?

LL-37 (Cathelicidin antimicrobial peptide, Variable; tissue-localised half-life, 100-500 mcg typical dose) differs from peers in the comparison table above. The principal points of difference relative to Oxytocin and Kisspeptin are mechanism, half-life, and target system. The full comparison is in the table above; specific stack selection depends on which dimension matters for the application.

Clinical Protocol

Start a LL-37 Protocol

Alukard provides physician-supervised women's health protocols with GMP-certified LL-37 and Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get Protocol

Quick Facts

Molecular weight: 4493 Da
Sequence length: 37 aa
Half-life: Variable; tissue-localised
WADA: Not on prohibited list
FDA: Unapproved
Research: Preclinical + small human series

Stack Partners

Oxytocin

Kisspeptin

GHK-Cu

Epithalon

PT-141

Research Note

All female physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for LL-37 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised women's health protocols

Start Your Female Physiology Protocol for LL-37

Alukard provides physician-supervised women's health protocols with Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised